Abstract Number: 9 • 2013 ACR/ARHP Annual Meeting
Domain 1 Is The Main Specificity Of Anti-β2glycoprotein I Antibodies In Systemic Autoimmune Diseases
Background/Purpose: Anti-β2glycoprotein I antibodies (a-β2GPI) are involved in the pathogenesis of the Antiphospholipid Syndrome (APS). Antibodies to the domain 1 of β2GP1 (a-β2GPI-D1) have been…Abstract Number: 10 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Targeting Domain 1 Of Beta 2 Glycoprotein I As Promising Marker In The Diagnosis and Risk Stratification Of The Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipids (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…Abstract Number: 12 • 2013 ACR/ARHP Annual Meeting
Phosphatidiyserine-Prothrombin Complex (aPS/PT) IgG Antibodies Correlate With Lupus Anticoagulant and Specific Pregnancy Complications In Patients With Antiphospholipid Syndrome
Background/Purpose: Criteria laboratory tests for antiphospholipid syndrome (APS) include lupus anticoagulant (LAC) as well as IgG and IgM antibodies for cardiolipin and beta2 glycoprotein. Of…Abstract Number: 13 • 2013 ACR/ARHP Annual Meeting
A MORE Specific Immunoassay For The Diagnosis Of APS
Background/Purpose: Anticardiolipin (aCL) antibody assays are sensitive for the detection of antiphospholipid antibodies (aPL) in patients with the Antiphospholipid syndrome (APS) but are known to…Abstract Number: 14 • 2013 ACR/ARHP Annual Meeting
Isotype Dependent Performance Of Beta2glycoprotein I Immunoassays In Two Diverse Patient Cohorts: Implications For Assay Harmonization and Standardization
Background/Purpose: The presence IgG and/or IgM beta2 glycoprotein I (β2GPI) antibodies are associated with thrombosis and/or pregnancy-related morbidity in antiphospholipid syndrome (APS) and/or systemic lupus…Abstract Number: 15 • 2013 ACR/ARHP Annual Meeting
Establishment Of Standardized International Units For IgM ANTI-β2glycoprotein Antibody Measurement
Background/Purpose: Recurrent IgG or IgM anti-β2glycoprotein (ab2GPI) antibody positivity is a key laboratory indicator for classification of antiphospholipid syndrome (APS). Considerable inter-laboratory variation still exists…Abstract Number: 16 • 2013 ACR/ARHP Annual Meeting
Only IgG and IgA β2glycoprotein I Antibody Isotypes Are Associated With Venous Thrombosis In Systemic Lupus Erythematosus
Background/Purpose: The current APS Classification Criteria recommend testing for IgG and IgM antibodies for β2glycoprotein I (β2GPI), and do not differentiate between primary and secondary…Abstract Number: 17 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Against Component Of Complement One Contribute To The Complement Activation and Clinical Manifestation Of Antiphospholipid Syndrome (APS) Especially In Refractory Cases
Background/Purpose: In the pathogenic mechanisms of antiphospholipid syndrome (APS), it is recognized that pathogenicity of antiphospholipid antibodies (aPL) has dominant effects. Complement is the part…Abstract Number: 18 • 2013 ACR/ARHP Annual Meeting
Clinical Correlates Of Positive Anti-Cardiolipin and β-2 Glycoprotein 1 Antibodies In a Cohort Of 110 Patients At Mayo Clinic
Background/Purpose: Testing for antiphospholipid antibodies is typically indicated for diagnosis and prognosis of antiphospholipid syndromes, however, selected patients undergo testing for other reasons. The clinical…Abstract Number: L2 • 2013 ACR/ARHP Annual Meeting
Proteome-Wide Analysis and CXCL4 As a Pathogenic Biomarker in Systemic Sclerosis
Background/Purpose: We hypothesized that plasmacytoid dendritic cells are implicated in the pathogenesis of systemic sclerosis via mechanisms beyond previously suggested type I interferon production. Methods:…Abstract Number: L4 • 2013 ACR/ARHP Annual Meeting
Apremilast in the Treatment of DMARD-Naïve Psoriatic Arthritis Patients: Results of a Phase 3 Randomized, Controlled Trial (PALACE 4)
Background/Purpose: Apremilast (APR), an oral PDE4 inhibitor, works intracellularly to modulate inflammatory mediators. PALACE 4 compared APR with placebo (PBO) in DMARD-naïve patients (pts) with…Abstract Number: L1 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of CT-P13 (Infliximab biosimilar) over Two Years in Patients with Rheumatoid Arthritis: Comparison Between Continued CT-P13 and Switching from Infliximab to CT-P13
Background/Purpose: CT-P13 is a biosimilar of infliximab (INX), approved by the European Medicines Agency. The objective of this open-label Phase 3 extension study was to…Abstract Number: L6 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Co-Morbid Depression Receiving Concurrent Antidepressant Therapy: A Randomized, 2-Way Crossover, Double-Blind, Placebo-Controlled Study
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain and often associated with mood disorders including depression. Approximately 50–70% of FM patients have a lifetime…Abstract Number: L5 • 2013 ACR/ARHP Annual Meeting
Improvement in High Density Lipoprotein Function in Early Rheumatoid Arthritis Patients Treated with Methotrexate Monotherapy or Combination Therapy in the Treatment of Early Rheumatoid Arthritis Trial
Background/Purpose: Abnormal function of high density lipoprotein (HDL) has been implicated as a potential mechanism for the increased cardiovascular disease (CVD) in patients with rheumatoid…Abstract Number: L3 • 2013 ACR/ARHP Annual Meeting
A Phase 2b, 12-Week Study of VX-509, an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis
Background/Purpose: VX-509 is an oral selective JAK3 inhibitor being evaluated for the treatment of rheumatoid arthritis (RA). The objective of this 24-week, randomized, placebo-controlled, double-blind,…
ACR Meeting Abstracts